TSHA - Taysha Gene Therapies Inc Stock Price, Fair Value and News

$1.87-0.01 (-0.53%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TSHA Price Action

Last 7 days

-5.5%

Last 30 days

-9.2%

Last 90 days

-14.9%

Trailing 12 Months

-16.8%

TSHA RSI Chart

TSHA Valuation

Market Cap

385.3M

Price/Earnings (Trailing)

-3.37

Price/Sales (Trailing)

29.93

Price/Free Cashflow

-5.09

TSHA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TSHA Fundamentals

TSHA Revenue

Revenue (TTM)

12.9M

Rev. Growth (Yr)

-53.57%

Rev. Growth (Qtr)

-67.4%

TSHA Earnings

Earnings (TTM)

-114.3M

Earnings Growth (Yr)

14.92%

Earnings Growth (Qtr)

13.02%

TSHA Profitability

Return on Equity

-105.02%

Return on Assets

-57.06%

Free Cashflow Yield

-19.65%

TSHA Investor Care

Shares Dilution (1Y)

217.91%

Diluted EPS (TTM)

-0.34

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	14.2M	12.9M	0	0
2023	5.7M	9.0M	12.2M	15.5M
2022	0	0	0	2.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

CEO	Mr. Sean P. Nolan
WEBSITE	tayshagtx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	65

Taysha Gene Therapies Inc Frequently Asked Questions

What is the ticker symbol for Taysha Gene Therapies Inc? What does TSHA stand for in stocks?

TSHA is the stock ticker symbol of Taysha Gene Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Taysha Gene Therapies Inc (TSHA)?

As of Tue Oct 29 2024, market cap of Taysha Gene Therapies Inc is 385.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TSHA stock?

You can check TSHA's fair value in chart for subscribers.

Is Taysha Gene Therapies Inc a good stock to buy?

The fair value guage provides a quick view whether TSHA is over valued or under valued. Whether Taysha Gene Therapies Inc is cheap or expensive depends on the assumptions which impact Taysha Gene Therapies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TSHA.

What is Taysha Gene Therapies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 29 2024, TSHA's PE ratio (Price to Earnings) is -3.37 and Price to Sales (PS) ratio is 29.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TSHA PE ratio will change depending on the future growth rate expectations of investors.